Two-year Follow-up of a Dose Reduction Strategy Trial of Biologics Adalimumab, Etanercept, and Ustekinumab in Psoriasis Patients in Daily Practice.

CONCLUSIONS: The proposed dose reduction strategy is effective for a significant part of patients and remains safe up to two years of follow-up. PMID: 33356686 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research